What problem does this paper attempt to address?

The paper attempts to address the issue of evaluating the incidence of Hand-Foot Syndrome (HFS) in cancer patients treated with capecitabine, its impact on chemotherapy, and the associated risk factors. Specifically, the study aims to: 1. **Evaluate the incidence of HFS**: Determine the overall incidence and severity of HFS in cancer patients receiving capecitabine treatment at Sarawak General Hospital in Malaysia. 2. **Analyze the impact of HFS on chemotherapy**: Examine the proportion of treatment interruptions and dose reductions due to HFS. 3. **Identify risk factors for HFS**: Investigate patient demographic characteristics, clinical features, and laboratory parameters associated with the occurrence of HFS through multivariable logistic regression analysis. ### Research Background Capecitabine is a commonly used oral chemotherapy drug for adjuvant or palliative treatment of various cancers. Although it has lower gastrointestinal and bone marrow toxicity compared to intravenous fluorouracil, it carries a higher risk of causing Hand-Foot Syndrome. HFS is a common dermatological adverse reaction characterized by erythema, dysesthesia, pain, skin cracking, desquamation, and ulcers on the palms and soles, significantly affecting patients' quality of life and potentially leading to treatment interruptions and dose adjustments. ### Research Objectives 1. **Evaluate the incidence of HFS**: Determine the overall incidence and severity of HFS in cancer patients receiving capecitabine treatment. 2. **Analyze the impact of HFS on chemotherapy**: Examine the proportion of treatment interruptions and dose reductions due to HFS. 3. **Identify risk factors for HFS**: Investigate patient demographic characteristics, clinical features, and laboratory parameters associated with the occurrence of HFS through multivariable logistic regression analysis. ### Research Methods - **Study Design**: Retrospective cross-sectional study. - **Study Population**: Adult cancer patients who received at least two cycles of capecitabine treatment at Sarawak General Hospital between April 1, 2021, and June 30, 2022. - **Data Collection**: Includes baseline demographic characteristics, clinical features, laboratory test results, and chemotherapy regimens of the patients. - **HFS Assessment**: Graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, v5.0). ### Key Findings - **Incidence of HFS**: Out of 369 patients, 185 (50.1%) developed HFS, with 14.6% experiencing grade ≥2 HFS. - **Impact on Treatment**: 40 (21.6%) patients had treatment adjustments due to HFS, including 37 (20.0%) treatment interruptions and 22 (11.9%) dose reductions. - **Risk Factors**: - **All-grade HFS**: Older age (OR 1.03, 95%CI 1.01, 1.06), history of prior chemotherapy (OR 2.09, 95%CI 1.22, 3.58), higher dose of capecitabine (OR 2.96, 95%CI 1.62, 5.38), longer treatment duration (OR 1.36, 95%CI 1.21, 1.51), folic acid supplementation (OR 3.27, 95%CI 1.45, 7.35), and lower neutrophil count (OR 0.77, 95%CI 0.66, 0.89). - **Grade ≥2 HFS**: Older age (OR 1.04, 95%CI 1.01, 1.08), female gender (OR 2.10, 95%CI 1.05, 4.18), Chinese ethnicity (OR 2.10, 95%CI 1.06, 4.18), higher dose of capecitabine (OR 2.62, 95%CI 1.28, 5.35), and non-use of calcium channel blockers (OR 0.21, 95%CI 0.06, 0.78). ### Conclusion This study provides real-world data on HFS induced by capecitabine in Malaysian patients and identifies several risk factors associated with the occurrence and exacerbation of HFS. These findings contribute to a better understanding of the mechanisms behind HFS and offer guidance for clinical management.

Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia

Hand-Foot Syndrome Presentation Post-Capecitabine Treatment in a Black Patient

Hand-foot syndrome caused by capecitabine: incidence, risk factors and the role of dermatological evaluation

Hand-foot Syndrome Related to Chemotherapy

Risk factors of capecitabine-induced hand-foot syndrome: a single-institution, retrospective study

Incidence and severity of hand-foot syndrome in cancer patients receiving infusional 5-fluorouracil or oral capecitabine-containing chemotherapy regimens

Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.

Possible Pathways of Capecitabine-Induced Hand–Foot Syndrome

Hand-foot syndrome and nail changes caused by capecitabine chemotherapy

Hand–foot syndrome induced by chemotherapy drug: Case series study and literature review

Impact of comprehensive nursing on hand-foot syndrome caused by oral capecitabine in breast cancer patients

Prevalence of hand-foot syndrome following chemotherapy for colorectal cancer: a systematic review and meta-analysis

Abstract PO1-20-09: A rare unilateral expression of hand-foot syndrome: a case report

Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer

Incidence and self-management of hand-foot syndrome in patients with colorectal cancer.

Optimizing quality of life: integrating palliative care for patients with hand-foot syndrome in oncology practice

Oral hyperpigmentation as an initial clinical aspect of hand foot syndrome

Effect of Chinese herbal compound LC09 on patients with capecitabine-associated hand-foot syndrome: A randomized, double-blind, placebo-controlled trial

Identification of the Novel Capecitabine Metabolites in Capecitabine-Treated Patients with Hand-Foot Syndrome

Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil

Proton Pump Inhibitors Ameliorate Capecitabine-induced Hand-Foot Syndrome in Patients With Breast Cancer: A Retrospective Study